Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents

Clinical trial NCT03452943 · COMPLETED

Trial details

NCT number: NCT03452943
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Status: COMPLETED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Tourette Syndrome

Start date: 2018-02-05
Primary completion: 2019-11-12
Enrollment: 119

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.